ME02834B - N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamid i n-(4-hidroksi-4-metilcikloheksil)- 4-(2-piridil)benzensulfonamid i nihova terapijska upotreba - Google Patents
N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamid i n-(4-hidroksi-4-metilcikloheksil)- 4-(2-piridil)benzensulfonamid i nihova terapijska upotrebaInfo
- Publication number
- ME02834B ME02834B MEP-2017-208A MEP2017208A ME02834B ME 02834 B ME02834 B ME 02834B ME P2017208 A MEP2017208 A ME P2017208A ME 02834 B ME02834 B ME 02834B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- pharmaceutically acceptable
- hydrate
- solvent
- following formula
- Prior art date
Links
- -1 4-HYDROXY-4-METHYL-CYCLOHEXYL Chemical class 0.000 title 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 78
- 150000003839 salts Chemical class 0.000 claims 33
- 239000002904 solvent Substances 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 206010065687 Bone loss Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000010029 ameloblastoma Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000000270 basal cell Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000002997 osteoclast Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (43)
1. Jedinjenje odabrano iz jedinjenja sledećih formula ili farmaceutski prihvatljivih soli, hidrata ili njihovih rastvora: i
2. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
3. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
4. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
5. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
6. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
7. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
8. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
9. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
10. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
11. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
12. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje odabrano iz jedinjenja sledećih formula ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
13. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
14. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
15. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
16. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
17. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
18. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
19. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
20. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvora:
21. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
22. Jedinjenje prema patentnom zahtevu 12, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
23. Jedinjenje prema patentnom zahtevu 1, koje je jedinjenje odabrano iz jedinjenja sledećih formula ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača: i
24. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
25. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
26. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
27. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
28. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
29. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
30. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
31. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
32. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
33. Jedinjenje prema patentnom zahtevu 23, koje je jedinjenje sledeće formule ili farmaceutski prihvatljive soli, hidrata ili njihovih rastvarača:
34. Sastav koji sadrži jedinjenje prema bilo kojem od patentnih zahteva od 1 do 33 i farmaceutski prihvatljivi nosač ili razblaživač.
35. Metoda za pripremanje sastava sadrži korak mešanja jedinjenja prema bilo kojem od patentnih zahteva od 1 do 33 i farmaceutski prihvatljivog nosača ili razblaživača.
36. Jedinjenje prema bilo kojem od patentnih zahteva od 1 do 33 za upotrebu u tretmanu ljudskog ili životinjskog tela putem terapije.
37. Jedinjenje prema patentnom zahtevu 36, gde tretman predstavlja tretman: reumatoidnog artritisa; psorijaze; psoriatičnog artritisa; hronične opstruktivne plućne bolesti (HOBP); astme; ateroskleroze; inflamatorne bolesti creva; ankiloznog spondilitisa; multiple skleroze; sistemskog eritemskog lupusa; Sjogrenovog sindroma; bolesti povezane sa osteoporozom, osteoporoze, oboljenja kostiju povezane sa kancerom ili Pagetovom bolešću, poremećaja povezanog sa gubitkom kostiju, kao što je gubitak kostiju koji je povezan sa prekomernom aktivnošću osteoklasta kod reumatoidnog artritisa; kancera, kao što je višestruki mielom, leukemija ili limfom ili čvrst tumor kancera, kao što je kancer bešike, kancer dojke (ženski i/ili muški), kancer debelog creva, kancer bubrežnih ćelija, kancera bubrega, kancera pluća, kancera pankreasa, kancera želuca, kancera prostate, kancera mozga, kancera kože, kancera štitnjače, ameloblastoma bazalnih ćelija ili melanoma; poremećaja povezanog sa fibrozom, kao što su sistemska skleroza ili skleroderma;ili retkog vaskulitisa, kao što je Beketova bolest.
38. Jedinjenje za upotrebu prema patentnom zahtevu 36, gde tretman predstavlja tretman: reumatoidnog artritisa; psorijaze; psoriatičnog artritisa; hronične opstruktivne plućne bolesti (HOBP); astme; ateroskleroze; inflamatorne bolesti creva; ankiloznog spondilitisa;
39. Jedinjenje za upotrebu prema patentnom zahtevu 36, gde tretman predstavlja tretman: multiple skleroze; sistematskog eritemskog lupusa; ili Sjogrenovog sindroma.
40. Jedinjenje za upotrebu prema patentnom zahtevu 36, gde tretman predstavlja tretman: bolesti povezane sa gubitkom kostiju, osteoporozom, bolestima kostiju povezanim sa kancerom ili Pagetovom bolešću.
41. Jedinjenje za upotrebu prema patentnom zahtevu 36, gde tretman predstavlja tretman: kancera, kao što je višestruki mijelom, leukemija ili limfom ili čvrst tumor kancera, kao što je kancer bešike, kancer dojke (ženski i/ili muški), kancer debelog creva, kancer bubrežnih ćelija, kancer bubrega, kancer pluća, kancer pankreasa, kancer želuca, kancer prostate, kancer mozga, kancer kože, karcinom tiroidne žlezde, ameloblastom bazalnih ćelija ili melanom.
42. Jedinjenje za upotrebu prema patentnom zahtevu 36, gde tretman predstavlja tretman: poremećaja povezanog sa fibrozom, kao što je sistematska skleroza ili skleroderma.
43. Jedinjenje za upotrebu prema patentnom zahtevu 36, gde tretman predstavlja tretman: retkog vaskulitisa kao što je Beketova bolest. 10
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1311361.8A GB201311361D0 (en) | 2013-06-26 | 2013-06-26 | Compounds and their therapeutic use |
| EP14735642.2A EP3013799B1 (en) | 2013-06-26 | 2014-06-24 | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use |
| PCT/GB2014/051921 WO2014207445A1 (en) | 2013-06-26 | 2014-06-24 | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02834B true ME02834B (me) | 2018-01-20 |
Family
ID=48998987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-208A ME02834B (me) | 2013-06-26 | 2014-06-24 | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamid i n-(4-hidroksi-4-metilcikloheksil)- 4-(2-piridil)benzensulfonamid i nihova terapijska upotreba |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US9624167B2 (me) |
| EP (1) | EP3013799B1 (me) |
| JP (1) | JP6360555B2 (me) |
| KR (1) | KR102151299B1 (me) |
| CN (1) | CN105492426B (me) |
| AU (1) | AU2014300745B2 (me) |
| BR (1) | BR112015031527B1 (me) |
| CA (1) | CA2915075C (me) |
| CY (1) | CY1119438T1 (me) |
| DK (1) | DK3013799T3 (me) |
| EA (1) | EA028077B1 (me) |
| ES (1) | ES2641758T3 (me) |
| GB (1) | GB201311361D0 (me) |
| HR (1) | HRP20171611T1 (me) |
| HU (1) | HUE034983T2 (me) |
| IL (1) | IL243103B (me) |
| LT (1) | LT3013799T (me) |
| ME (1) | ME02834B (me) |
| MX (1) | MX374328B (me) |
| NZ (1) | NZ715192A (me) |
| PL (1) | PL3013799T3 (me) |
| PT (1) | PT3013799T (me) |
| RS (1) | RS56256B1 (me) |
| SG (1) | SG11201510646SA (me) |
| SI (1) | SI3013799T1 (me) |
| SM (1) | SMT201700503T1 (me) |
| WO (1) | WO2014207445A1 (me) |
| ZA (1) | ZA201600202B (me) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| LT3262028T (lt) * | 2014-12-17 | 2022-01-10 | Pimco 2664 Limited | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamido ir n-(-4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamido junginiai ir jų terapinis panaudojimas |
| GB201813312D0 (en) | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| GB201905520D0 (en) * | 2019-04-18 | 2019-06-05 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| EP4431090A1 (en) | 2023-03-15 | 2024-09-18 | Istesso 1 Limited | Solfonamides acting as mitochondrial complex i modulator compounds |
| GB202308547D0 (en) | 2023-06-08 | 2023-07-26 | Istesso 2 Ltd | Tnf inhibitor combination therapies |
| GB202309515D0 (en) | 2023-06-23 | 2023-08-09 | Istesso 2 Ltd | JAK inhibitor and IL-6 inhibitor combination therapies |
| GB202315822D0 (en) | 2023-10-16 | 2023-11-29 | Istesso 3 Ltd | Anti-fibrotic combination therapeutics |
| GB202317050D0 (en) | 2023-11-07 | 2023-12-20 | Istesso 2 Ltd | Disease modifying anti-rheumatic drug combination therapies |
| EP4647071A1 (en) | 2024-05-10 | 2025-11-12 | Istesso Therapeutics Limited | Mitochondrial complex i modulator for use in the treatment of arthritis |
| GB202411554D0 (en) | 2024-08-06 | 2024-09-18 | Istesso 2 Ltd | NF-kB inhibitor combination therapies |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB597810A (en) | 1943-04-12 | 1948-02-04 | Gen Printing Ink Corp | Improvements in or relating to derivatives of diphenyl |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| US4119784A (en) | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| CZ132798A3 (cs) | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Inhibitory proteázy |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| EP0888344A1 (en) | 1996-03-15 | 1999-01-07 | The Du Pont Merck Pharmaceutical Company | Spirocycle integrin inhibitors |
| WO1998003166A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
| HUP0000641A3 (en) | 1996-10-16 | 2001-02-28 | American Cyanamid Company Madi | Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them |
| WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| AU734302B2 (en) | 1997-05-08 | 2001-06-07 | Smithkline Beecham Corporation | Protease inhibitors |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| PT877019E (pt) | 1997-05-09 | 2002-05-31 | Hoechst Ag | Acidos diaminocarboxilicos substituidos |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| JP2002501054A (ja) | 1998-01-23 | 2002-01-15 | アヴェンティス ファルマ ドイチェラント ゲーエムベーハー | 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体 |
| EP1053226A1 (en) | 1998-02-04 | 2000-11-22 | Novartis AG | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| DE19815547C1 (de) | 1998-04-07 | 1999-12-02 | Joachim Schmidt | Haftmittel für Zahnprothesen |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| CN1418210A (zh) | 2000-03-21 | 2003-05-14 | 宝洁公司 | 含有碳环侧链的n－取代金属蛋白酶抑制剂 |
| WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| US6849635B2 (en) | 2001-05-07 | 2005-02-01 | Smithkline Beecham Corporation | Sulfonamides |
| NZ531153A (en) | 2001-08-09 | 2005-10-28 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| GB0126157D0 (en) | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| TW200305396A (en) | 2002-03-27 | 2003-11-01 | Shionogi & Co | Cartilage extracellular matrix degradation |
| MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| DE10251170A1 (de) | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| ES2298753T3 (es) | 2003-05-07 | 2008-05-16 | The University Court Of The University Of Aberdeen | Cetonas y cetonas reducidas como agentes terapeuticos para el tratamiento de enfermedades oseas. |
| JPWO2004106290A1 (ja) | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| AR046330A1 (es) | 2003-09-09 | 2005-12-07 | Japan Tobacco Inc | Inhibidor de dipeptidilpeptidasa iv |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| BRPI0417687A (pt) | 2003-12-19 | 2007-04-03 | Pfizer | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade |
| EP1723132A1 (en) | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
| GB0405193D0 (en) | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| US20080255240A1 (en) | 2004-05-05 | 2008-10-16 | Novo Nordisk A/S | Sulfonamide Derivatives |
| GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| WO2005123089A2 (en) | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| CA2584413A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| EA200702498A1 (ru) | 2005-06-16 | 2008-06-30 | Пфайзер Инк. | N-(пиридин-2-ил)сульфонамидные производные |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| EP2774925B1 (en) | 2005-11-08 | 2016-12-28 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of ATP-binding cassette transporters |
| EA019879B1 (ru) | 2005-12-29 | 2014-07-30 | Лексикон Фармасьютикалз, Инк. | Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные |
| US7560597B2 (en) | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| WO2010025235A1 (en) | 2008-08-29 | 2010-03-04 | Regents Of The University Of Michigan | Selective ligands for the dopamine 3 (d3) receptor and methods of using the same |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| LT3262028T (lt) | 2014-12-17 | 2022-01-10 | Pimco 2664 Limited | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamido ir n-(-4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamido junginiai ir jų terapinis panaudojimas |
-
2013
- 2013-06-26 GB GBGB1311361.8A patent/GB201311361D0/en not_active Ceased
-
2014
- 2014-06-24 SM SM20170503T patent/SMT201700503T1/it unknown
- 2014-06-24 JP JP2016522860A patent/JP6360555B2/ja active Active
- 2014-06-24 DK DK14735642.2T patent/DK3013799T3/en active
- 2014-06-24 PL PL14735642T patent/PL3013799T3/pl unknown
- 2014-06-24 EA EA201592308A patent/EA028077B1/ru unknown
- 2014-06-24 SI SI201430364T patent/SI3013799T1/sl unknown
- 2014-06-24 CA CA2915075A patent/CA2915075C/en active Active
- 2014-06-24 RS RS20170876A patent/RS56256B1/sr unknown
- 2014-06-24 NZ NZ715192A patent/NZ715192A/en unknown
- 2014-06-24 EP EP14735642.2A patent/EP3013799B1/en active Active
- 2014-06-24 LT LTEP14735642.2T patent/LT3013799T/lt unknown
- 2014-06-24 ME MEP-2017-208A patent/ME02834B/me unknown
- 2014-06-24 MX MX2015016914A patent/MX374328B/es active IP Right Grant
- 2014-06-24 HU HUE14735642A patent/HUE034983T2/en unknown
- 2014-06-24 CN CN201480047140.2A patent/CN105492426B/zh active Active
- 2014-06-24 KR KR1020167002015A patent/KR102151299B1/ko active Active
- 2014-06-24 BR BR112015031527-5A patent/BR112015031527B1/pt active IP Right Grant
- 2014-06-24 AU AU2014300745A patent/AU2014300745B2/en active Active
- 2014-06-24 ES ES14735642.2T patent/ES2641758T3/es active Active
- 2014-06-24 US US14/899,422 patent/US9624167B2/en active Active
- 2014-06-24 WO PCT/GB2014/051921 patent/WO2014207445A1/en not_active Ceased
- 2014-06-24 PT PT147356422T patent/PT3013799T/pt unknown
- 2014-06-24 SG SG11201510646SA patent/SG11201510646SA/en unknown
- 2014-06-24 HR HRP20171611TT patent/HRP20171611T1/hr unknown
-
2015
- 2015-12-14 IL IL243103A patent/IL243103B/en active IP Right Grant
-
2016
- 2016-01-11 ZA ZA2016/00202A patent/ZA201600202B/en unknown
-
2017
- 2017-04-11 US US15/484,256 patent/US9796670B2/en active Active
- 2017-10-11 CY CY20171101060T patent/CY1119438T1/el unknown
- 2017-10-17 US US15/786,021 patent/US10029979B2/en active Active
-
2018
- 2018-07-17 US US16/037,048 patent/US10233147B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171611T1 (hr) | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena | |
| HRP20211877T1 (hr) | Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba | |
| NZ711976A (en) | Processes and intermediates for making a jak inhibitor | |
| JP2016529218A5 (me) | ||
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| JO3809B1 (ar) | مركب (6S، 9aS)-N- بنزيل -6-[(4- هيدروكسي فينيل) ميثيل]-4، 7- داي أوكسو -8-({6-[3-(بيبرازين -1- يل) أزيتيدين -1- يل] بيريدين -2- يل} ميثيل)-2-(بروب-2-إين- 1- يل)- أوكتا هيدرو -1H- بيرازينو [2، 1-c][1، 2، 4] ترايازين -1- كربوكساميد | |
| PH12016500359A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| PH12014502341A1 (en) | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | |
| JP2014521625A5 (me) | ||
| ME02892B (me) | Hemijska jedinjenja | |
| JP2017525753A5 (me) | ||
| MX2012015105A (es) | Inhibidores de cinasa de regulacion mediante señal de apoptosis. | |
| MX2021001583A (es) | Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso. | |
| TN2015000102A1 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors | |
| EP3019595A4 (en) | THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS | |
| NZ709248A (en) | Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors | |
| NZ597596A (en) | Bicyclic aryl sphingosine 1-phosphate analogs | |
| MX354482B (es) | Proceso de elaboración para derivados de pirimidina. | |
| MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| JP2018509380A5 (me) | ||
| JP2017514910A5 (me) | ||
| PH12018500533A1 (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| BR112013021941A2 (pt) | agente terapêutico para tumor | |
| HRP20241103T1 (hr) | 2,4-di-(skupina koja sadrži dušik)-supstituirani pirimidinski spoj i postupak pripreme i njegova upotreba |